Pharmacotherapy for Irritable Bowel Syndrome.

Pharmacotherapy for Irritable Bowel Syndrome.
复制标题

肠易激综合征的药物治疗。

DOI:
10.3390/jcm6110101
复制
发表时间:
2017-10-27
影响因子:
3.9
通讯作者:
Ford AC
Ford AC
中科院分区:
医学2区
文献类型:
--
作者:
Camilleri M;Ford AC

文献摘要

参考文献

被引文献

相似文献

肠易激综合征(IBS)是一种脑肠轴紊乱,其病理生理机制包括结肠动力改变、胆汁酸代谢、神经激素调节、免疫功能障碍、上皮屏障和肠道分泌特性的改变。本文综述了目前治疗肠易激综合征的机制、有效性和安全性,以及正在进行第三阶段试验的药物。尽管针对肠易激综合征的分泌性、运动性和不可吸收抗生素的药物的引入为IBS的肠道功能障碍提供了选择,但对于有效的治疗--特别是针对IBS的疼痛部分--仍然有很大的需求没有得到满足。
Irritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments—particularly for the pain component of IBS—although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS.
DOI: 10.1007/s10620-015-3858-7
发表时间: 2016-02-01
影响因子: 3.1
作者:
Cash, Brooks D.;Epstein, Michael S.;Shah, Syed M.
通讯作者: Shah, Syed M.
DOI: 10.1016/s0016-5085(03)00669-3
发表时间: 2003-07-01
期刊: GASTROENTEROLOGY
影响因子: 29.4
作者:
Drossman, DA;Toner, BB;Bangdiwala, SI
通讯作者: Bangdiwala, SI
DOI: 10.1002/gps.4517
发表时间: 2017-07-01
影响因子: 4
作者:
Breining, Alice;Bonnet-Zamponi, Dominique;Leperre-Desplanques, Armelle
通讯作者: Leperre-Desplanques, Armelle
DOI: 10.1136/gutjnl-2016-313425
发表时间: 2017-05-01
期刊: GUT
影响因子: 24.5
作者:
Camilleri, Michael;Boeckxstaens, Guy
通讯作者: Boeckxstaens, Guy
DOI: 10.1038/ajg.2012.254
发表时间: 2012-11-01
影响因子: 9.8
作者:
Chey, William D.;Lembo, Anthony J.;Johnston, Jeffrey M.
通讯作者: Johnston, Jeffrey M.